文献速递食管胃疾病与幽门螺杆菌

2018年欧洲幽门螺杆菌抗生素耐药与社区抗生素消耗的关系

Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community.
PubMed 文献 · Gut · 2021-04-09

研究前瞻性评估2018年欧洲18国24中心1211例成人幽门螺杆菌原发耐药率,并分析2008-2017年社区抗生素消耗与耐药关联。结果显示克拉霉素耐药21.4%、左氧氟沙星15.8%、甲硝唑38.9%,中/西/南欧高于北欧;大环内酯类和喹诺酮类消耗与相应耐药显著相关。结论建议多数欧洲国家启动克拉霉素或左氧氟沙星治疗前应先行药敏检测。

要点

  • 欧洲幽门螺杆菌原发耐药率:克拉霉素21.4%、左氧氟沙星15.8%、甲硝唑38.9%。
  • 中/西/南欧耐药率显著高于北欧。
  • 社区大环内酯类和喹诺酮类消耗与相应耐药显著相关。

核心结论

  • 研究证实欧洲国家社区大环内酯类和喹诺酮类消耗与幽门螺杆菌相应耐药呈正相关。
  • 因此,多数欧洲国家不应在未做药敏检测的情况下启动克拉霉素或左氧氟沙星治疗。

研究设计与样本

  • 前瞻性研究,按标准化方案在18个欧洲国家的24个中心调查幽门螺杆菌原发耐药比例及危险因素。
  • 纳入1211例成人患者,收集2008-2017年社区抗生素消耗数据。
  • 采用广义线性混合模型评估抗生素消耗与耐药数据的关联,以Akaike信息准则选择最佳拟合模型。

主要发现

  • 1211例成人患者中,幽门螺杆菌耐药率:克拉霉素21.4%、左氧氟沙星15.8%、甲硝唑38.9%。
  • 中/西/南欧的耐药率显著高于北欧。
  • 最佳拟合模型为使用2013年消耗数据的泊松分布。
  • 克拉霉素耐药与社区大环内酯类消耗(p=0.0003)及中间作用大环内酯类消耗(p=0.005)显著相关。
  • 左氧氟沙星耐药与社区喹诺酮类消耗(p=0.0002)及第二代喹诺酮类消耗(p=0.0003)显著相关。

临床怎么用

  • 在多数欧洲国家,启动含克拉霉素或左氧氟沙星的幽门螺杆菌治疗前应进行药敏检测。
  • 社区大环内酯类和喹诺酮类消耗水平可提示相应耐药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our aim was to prospectively assess the antibiotic resistance rates in Helicobacter pylori strains in Europe in 2018 and to study the link between antibiotic consumption in the community and H. pylori resistance levels in the different countries. DESIGN: The proportion of primary antibiotic resistance cases of H. pylori and their corresponding risk factors were investigated in 24 centres from 18 European countries according to a standardised protocol. Data on antibiotic consumption in the community were collected for the period 2008-2017. The link between antibiotic consumption and resistance data was assessed using generalised linear mixed models. The model with the best fit was selected by means of the Akaike Information Criterion. RESULTS: H. pylori resistance rates for the 1211 adult patients included were 21.4% for clarithromycin, 15.8% for levofloxacin and 38.9% for metronidazole and were significantly higher in Central/Western and Southern than in the Northern European countries.The best model fit was obtained for the Poisson distribution using 2013 consumption data. A significant association was found between H. pylori clarithromycin resistance and consumption in the community of macrolides (p=0.0003) and intermediate-acting macrolides (p=0.005), and between levofloxacin resistance and consumption of quinolones (p=0.0002) and second-generation quinolones (p=0.0003). CONCLUSION: This study confirms the positive correlation between macrolide and quinolone consumption in the community and corresponding H. pylori resistance in European countries. Hence, H. pylori treatment with clarithromycin and levofloxacin should not be started without susceptibility testing in most European countries.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021. PMID: 33837118. doi:10.1136/gutjnl-2021-324032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。